Logo image of CURX

CURANEX PHARMACEUTICALS INC (CURX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CURX - US23126K1060 - Common Stock

0.36 USD
0 (0%)
Last: 1/14/2026, 1:37:08 PM
Fundamental Rating

3

CURX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. CURX has a great financial health rating, but its profitability evaluates not so good. CURX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CURX has reported negative net income.
CURX Yearly Net Income VS EBIT VS OCF VS FCFCURX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -100K -200K -300K -400K -500K

1.2 Ratios

  • CURX has a better Return On Assets (-10.45%) than 65.26% of its industry peers.
  • With a decent Return On Equity value of -10.59%, CURX is doing good in the industry, outperforming 73.16% of the companies in the same industry.
Industry RankSector Rank
ROA -10.45%
ROE -10.59%
ROIC N/A
ROA(3y)-97.88%
ROA(5y)N/A
ROE(3y)-100.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CURX Yearly ROA, ROE, ROICCURX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CURX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CURX Yearly Profit, Operating, Gross MarginsCURX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -20 -40 -60

More info and screens

9

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CURX has about the same amount of shares outstanding.
  • There is no outstanding debt for CURX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CURX Yearly Shares OutstandingCURX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M 25M
CURX Yearly Total Debt VS Total AssetsCURX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100K 200K 300K 400K 500K

2.2 Solvency

  • CURX has an Altman-Z score of 33.36. This indicates that CURX is financially healthy and has little risk of bankruptcy at the moment.
  • CURX's Altman-Z score of 33.36 is amongst the best of the industry. CURX outperforms 92.63% of its industry peers.
  • CURX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 33.36
ROIC/WACCN/A
WACCN/A
CURX Yearly LT Debt VS Equity VS FCFCURX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200K -200K 400K -400K

2.3 Liquidity

  • A Current Ratio of 77.52 indicates that CURX has no problem at all paying its short term obligations.
  • CURX's Current ratio of 77.52 is amongst the best of the industry. CURX outperforms 99.47% of its industry peers.
  • A Quick Ratio of 77.52 indicates that CURX has no problem at all paying its short term obligations.
  • CURX's Quick ratio of 77.52 is amongst the best of the industry. CURX outperforms 99.47% of its industry peers.
Industry RankSector Rank
Current Ratio 77.52
Quick Ratio 77.52
CURX Yearly Current Assets VS Current LiabilitesCURX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100K 200K 300K 400K 500K

More info and screens

0

3. Growth

3.1 Past

  • CURX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1757.14%.
EPS 1Y (TTM)-1757.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CURX Yearly Revenue VS EstimatesCURX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 5K 10K 15K 20K 25K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CURX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CURX Price Earnings VS Forward Price EarningsCURX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CURX Per share dataCURX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CURX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CURANEX PHARMACEUTICALS INC

NASDAQ:CURX (1/14/2026, 1:37:08 PM)

0.36

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.01%
Inst Owner Change0%
Ins Owners67.82%
Ins Owner Change0%
Market Cap10.20M
Revenue(TTM)N/A
Net Income(TTM)-1.51M
AnalystsN/A
Price TargetN/A
Short Float %0.76%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.45%
ROE -10.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-97.88%
ROA(5y)N/A
ROE(3y)-100.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 77.52
Quick Ratio 77.52
Altman-Z 33.36
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1757.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1404.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-555500%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-555500%
OCF growth 3YN/A
OCF growth 5YN/A

CURANEX PHARMACEUTICALS INC / CURX FAQ

What is the ChartMill fundamental rating of CURANEX PHARMACEUTICALS INC (CURX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CURX.


What is the valuation status of CURANEX PHARMACEUTICALS INC (CURX) stock?

ChartMill assigns a valuation rating of 0 / 10 to CURANEX PHARMACEUTICALS INC (CURX). This can be considered as Overvalued.


How profitable is CURANEX PHARMACEUTICALS INC (CURX) stock?

CURANEX PHARMACEUTICALS INC (CURX) has a profitability rating of 1 / 10.